Pharmacoeconomic Analysis of Direct Activity Antiviral Drugs Used for Treatment of Genotype 1 Chronic Hepatitis C
N. Z. Musina *
I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation and Moscow Institute of Physics and Technology (State University), Dolgoprudny, Russian Federation.
A. G. Savilova
Moscow Institute of Physics and Technology (State University), Dolgoprudny, Russian Federation.
O. M. Korzinov
Moscow Institute of Physics and Technology (State University), Dolgoprudny, Russian Federation.
*Author to whom correspondence should be addressed.
Abstract
Aims: Hepatitis C is one of the most important global health care problems. The goal of this study was to perform a pharmacoeconomic analysis of therapeutic schemes used in treatment of patients with genotype 1 chronic HCV by using direct-acting antiviral agents in combination with pegylated interferons and ribavirin.
Study Design: In the current study comparison of therapeutic schemes used in treatment of patients with genotype 1 chronic HCV by using direct-acting antiviral agents in combination with pegylated interferons and ribavirin was made.
Place and Duration of Study: Moscow Institute of Physics and Technology (State University), Department of Biological and Medical Physics, Laboratory of government programs and development projects in life sciences (April 2015 - November 2015).
Methodology: In the current study Markov decision process model was built in order to assess long-term costs and efficacy of preparations under study. Comparison of therapeutic schemes for chronic HCV infection treatment was performed with the use of cost-effectiveness and cost-utility analysis. In costs-effectiveness analysis, therapeutic schemes for CHC treatment that include telaprevir, boceprevir and simeprevir, life years gained (LYG) and quality adjusted life years (QALY) served as a criterion of benefit in costs-effectiveness and cost-utility analysis respectively.
Results: Pharmacoeconomic analysis of treatment of chronic hepatitis C viral infection showed that the best combination of costs and effectiveness was observed in combined treatment with the use of pegylated interferon, ribavirin and boceprevir in treatment-naïve patients as well as patients with unsuccessful treatment experience.
Conclusion: Our results showed that combined therapy with the use of boceprevir is the most pharmacoeconomically justified in comparison with telaprevir and simeprevir-based treatment.
Keywords: Hepatitis C, boceprevir, telaprevir, simeprevir